DUBLIN--(BUSINESS WIRE)--The "Global Cancer CDK Inhibitors Market & Clinical Pipeline Outlook 2022" report has been added to Research and Markets' offering.
"Global Cancer CDK Inhibitors Market & Clinical Pipeline Outlook 2022" report gives comprehensive insight on clinical and non-clinical parameters related to emergence and growth of CDK inhibitors in cancer therapy.
As per report findings, CDK inhibitors have emerged as new growth frontier for the organizations involved in the research, development, licensing and commercialization of targeted cancer therapies. There are 2 CDK inhibitors commercially available in the market for the treatment of cancer and more than 45 CDK inhibitors are in various phases of clinical pipeline.
Key Topics Covered:
1. Cyclin Dependent Kinase Inhibitors -An Introduction to a Promising Cancer Therapeutic
1.1 History of Discoveries Leading to Cyclin Dependent Kinase Inhibitor Drug
1.2 An Insight into Cell Cycle, Cyclin & the Role of CDKs
1.3 Cyclin Dependent Kinase Inhibitors for Cancer - An Overview
2. Cyclin Dependent Kinase Pathway as Targets for Cancer Therapy
2.1 CDK Pathway & Cell Cycle Checkpoints
2.2 Role of Cyclin Dependent Kinases in Carcinogenesis
2.3 Cyclin Dependent Kinases Associated With Various Cancers
3. Selectivity & Working Mechanism of a Cancer CDKs Inhibitor
4. Types of CDK Inhibitors
4.1 ATP Competitive CDK Inhibitors
4.2 ATP Non Competitive Inhibitors
4.3 Allosteric Inhibitors
5. Recent Advances in the CDKs Related Cancer Therapy
5.1 CDK 4/6 in Breast Cancer
5.2 Role of CDKs in Hematological Malignancies
6. CDK Inhibitors as Combinational Cancer Therapeutic
7. Current Market Scenario of Cancer CDKs inhibitors
7.1 Commercial Aspects of CDKs Inhibitor
7.2 Key Market Players in the Cancer CDKs Inhibitor Market
7.3 Global Cancer CDK-Inhibitors Pipeline Overview
8. Marketed Cancer CDK Inhibitors Clinical Insight
8.1 Palbociclib (Ibrance)
8.2 Ribociclib (Kisqali)
9. Price Analysis of Cancer CDKs Inhibitors
9.1 Commercially Available CDK Inhibitors Price Analysis
9.1.1 Cost of Approved Cancer CDKs Inhibitor
9.1.2 Average Cost of CDKs Inhibitors Currently Under Research
9.2 Comparison of Cancer CDKs inhibitor to other Cancer Drugs & Therapies
10. Driving Factors of the Cancer CDKs Inhibitors Market
10.1 Accelerated Approval of Previously Introduced CDKs Inhibitor for Breast Cancer- Ibrance
10.2 Increasing Prevalence of Cancer
10.3 Presence of a Robust Clinical Pipeline
10.4 Advancement in Research & Development
10.5 High Unmet Medical Needs
11. CDK Inhibitors Market Challenges
11.1 High Cost Factor Associated with Cancer CDKs Inhibitor
11.2 Scientific & Technical Limitations
11.3 Side Effects & unreliable Efficacy
11.4 Competition from other Cancer Therapeutic Segments
11.5 Slow FDA Approvals
11.6 Commercial Challenges
12. Anticipation Regarding the Future of CDKs Inhibitor Cancer Therapy Market
13. Global Cancer CDK Inhibitors Clinical Trials Insight by Company, Indication & Phase
13.1 Preclinical
13.2 Phase-I
13.3 Phase-I/II
13.4 Phase-II
13.5 Phase-III
13.6 Preregistration
14. Competitive Landscape
- Amgen
- Anygen
- Astex
- Bayer Pharmaceuticals
- BioCAD
- Cyclacel
- Eli - Lilly
- G1 Therapeutics
- Merck
- Nerviano Medical Science
- Pfizer
- Piramal Life
- Sanofi-Aventis
- Syros Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/research/j62z7q/global_cancer_cdk
